Utama › Kanser Kolon › Tennessee › Nashville
Kajian klinikal Kanser Kolon di Nashville, TN
16 kajian untuk Kanser Kolon sedang mencari peserta di lokasi dalam dan sekitar Nashville (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study of PHN-012 in Patients With Advanced Solid Tumors
Mengambil pesertaFasa 1
- PHN-012-001 Site, Nashville
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Mengambil pesertaFasa 3
- Henry-Joyce Cancer Clinic, Nashville
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Mengambil pesertaFasa 1/2
- Sarah Cannon Research Institue, Nashville
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Mengambil pesertaFasa 1/2
- Tennessee Oncology, PLLC, Nashville
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Mengambil pesertaFasa 1/2
- GSK Investigational Site, Nashville
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Mengambil pesertaFasa 2/3
- Vanderbilt University/Ingram Cancer Center, Nashville
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Mengambil pesertaFasa 1
- Xencor Investigative Site, Nashville
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Mengambil pesertaFasa 1
- Sarah Cannon, SCRI Oncology Partners, Nashville
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Mengambil pesertaFasa 1/2
- Vanderbilt University Medical Center, Nashville
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)
Mengambil pesertaFasa 2
- SCRI Oncology Partners, Nashville
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Mengambil pesertaFasa 1
- Research Site, Nashville
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Mengambil pesertaFasa 1
- Sarah Cannon Research Institute, Nashville
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Mengambil pesertaFasa 1/2
- Sarah Cannon Research Institute, Nashville
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- Sarah Cannon Research Institute, Nashville
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
Mengambil pesertaKajian pemerhatian
- Veterans Affairs Medical Center - Nashville, Nashville
- Vanderbilt-Ingram Cancer Center, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Nashville
Kajian Kanser Kolon di bandar lain
- Boston, MA22 kajian
- New York City, NY22 kajian
- Houston, TX20 kajian
- Los Angeles, CA16 kajian
- St. Louis, MO15 kajian
- Arlington, VA15 kajian
- Chicago, IL14 kajian
- San Antonio, TX14 kajian
- Baldwin Park, CA14 kajian
- Baltimore, MD13 kajian
- Tampa, FL13 kajian
- Washington, DC12 kajian
Kajian lain di Nashville
- Kanser Paru-paru Bukan Sel Kecil97 kajian
- Kanser Payudara81 kajian
- Kanser Metastatik70 kajian
- Kanser Kolorektal69 kajian
- Kanser (semua jenis)65 kajian
- Kanser Ovari49 kajian
- Kanser Prostat43 kajian
- Kanser Paru-paru40 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher39 kajian
- Kanser Pankreas39 kajian
- Kanser Endometrium38 kajian
- Melanoma33 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.